H omozygous β-thalassemia is an inherited disorder of hemoglobin resulted from an imbalance of β-globin chain synthesis. 1 The most important cause of anemia in β-thalassemia is ineffective erythropoiesis with intramedullary destruction of a variable proportion of the developing red cell precursors. 2 The only treatment available in developing countries for thalassemic patients is regular blood transfusions. 2, 3 Patients who do not receive transfusions show a two to three-fold increase in the absorption of heme iron in comparison to normal subjects. 4 Regular transfusions may double the rate of iron accumulation. 1 In the absence of chelating therapy, the accumulation of iron results in progressive dysfunction of the heart, liver, and endocrine glands. [5] [6] [7] Impaired glucose tolerance (IGT) and diabetes mellitus (DM) may be the consequences of β-cell destruction secondary to iron overload, insulin resistance, hepatitis virus infection (mainly hepatitis C) and genetic factors. 1 Sanctis et al found that 5-15% of thalassemic patients suffered from IGT and DM.
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The onset of diabetes mellitus in the majority of patients occurred after the age of ten. 1 Among 392 thalassemic patients aged 16 to 25 years in Karagiorga's study who underwent the OGTT, 2.3% suffered from DM, while 17% had IGT. About 44% of the DM and 29% of the IGT had family history of diabetes mellitus in first and second degree relatives. 5 Anastasi found that 20.6% of thalassemic patients aged 10-27 years suffered from DM and 30.4% had IGT. Hyperinsulinism was detected in 37.9% of them who had IGT. 6 In 1999, Setiawan studied the prevalence of IGT and DM in thalassemic patients aged 9-22 years at Cipto Mangunkusumo Hospital. Of 115 patients, 2.6% had DM and 14.8% had IGT. None of them had family history of diabetes mellitus. In her study, she found no correlation neither between serum ferritin level and serum fasting glucose nor between serum ferritin level and total volume of transfusions. 8 The aim of this study was to evaluate the presence of impaired glucose tolerance, diabetes mellitus, and insulin resistance in patients with b thalassemia major.
Methods
We conducted a descriptive cross sectional study in May, 2002. Forty-eight patients with β thalassemia major who visited the Thalassemia Outpatient Clinic at Cipto Mangunkusumo Hospital were recruited. This study was approved by the Committee of Medical Research Ethics of Medical School, University of Indonesia. The inclusion criteria were patients with confirmed diagnosis of β thalassemia major, aged 10 to 18 years, and their parents agreed and signed the informed consent. Questionnaire was completed by interview recording family history of diabetes mellitus in first and second degree relatives, total volume of transfusions, age of onset, and duration of illness. All patients underwent OGTT by receiving 1.75g/kg body weight of glucose (maximum dose 75 g) after an 8 hour-fast. Venous blood samples for serum iron (SI), total iron binding capacity (TIBC), glucose and insulin determination were obtained before receiving oral glucose. At 120 minutes after oral glucose administration, glucose and insulin determination were done. All blood samples were examined at Prodia Laboratory. The criteria of the American Diabetes Association 1998 was used to evaluate the glucose tolerance. 9 Iron overload was defined when the serum transferrin saturation was 55% or more. Insulin resistance was confirmed if the homeostasis model assessment (HOMA) score was 4 or more. 10 All data were transferred to SPSS 10.0 computer program.
Results
Among forty-eight thalassemic patients (27 males and 21 females), thirteen (27%) had family history of diabetes mellitus. About 75% of the patients had already received more than 20 liters of blood transfusion. Iron overload occurred in 58% of the thalassemic patients ( Table 1) . Sixteen patients who received over 20 liters of blood transfusion did not have iron overload (Figure 1) . One patient developed impaired glucose tolerance (2%) at the age of 17 years and had family history of diabetes mellitus.
The total volume of blood transfusions was 87.93 liters and the serum transferrin saturation was 26.2%. Diabetes mellitus was present in three patients (6%), at the age of 15.5 years in one patient and 18 years in the two other patients. Two of them various organs, particularly the liver, pancreas, and heart. Generally, the higher total volume of blood transfusions, the higher iron overload would be. In the sixteen subjects of this study, there was no iron overload although they had already received more than 20 liters of blood transfusion. It seems that these patients had good compliance of iron chelation therapy, unfortunately there was no available data. On the other hand, some patients who had lower total volume of blood transfusions already suffered from iron overload. The reason of this condition was unknown. In this study, the prevalence of IGT and DM in thalassemic patients was lower than that of other studies. It seems that the different range of age and the number of samples were the reasons for the difference. The other possibility is that the test for hepatitis B or C virus infection which influences the prevalence of IGT and DM, was not done. Chern et al in Taiwan found that 56.3% of thalassemic patients with hepatitis C virus infection had DM. 11 Up till now, the pathogenesis of DM in thalassemia remains unclear, whether it is due to insulin deficiency, insulin resistance, or combination of them. In this study, all the abnormal glucose tolerance patients did not show insulin resistance (the HOMA calculation was under 4 in all patients). Deficiency of insulin was also not proven in this study, since all of the diabetic patients had normal fasting insulin level.
In conclusion, the prevalence of glucose metabolism derangement in thalassemic patients was low (2% had family history of diabetes mellitus. Total volumes of blood transfusions were 44.65 liters, 103 liters, and 100.7 liters respectively. Serum transferrin saturation levels were 96%, 74.6%, and 65.5% ( Table 2) .
After performing OGTT, we divided the patients into two groups: those with normal glucose tolerance and those with abnormal one (IGT and DM). The group with abnormal glucose tolerance had younger age of onset of thalassemia, longer duration of illness, and higher total volume of blood transfusions than that with normal glucose tolerance. In the group with abnormal glucose tolerance, the mean serum transferrin saturation was higher than in that with normal glucose tolerance ( Table 3) . We found no insulin resistance in all thalassemic patients, whereas only 4 patients (8%) had abnormal glucose tolerance.
Discussion
The limitations of this study were unknown level of compliance of the use of iron-chelation and the lack of data regarding hepatitis B and C virus infection, which are the risk factors of diabetes mellitus in thalassemia. 5, 11 The gold standard to evaluate the sensitivity of insulin is euglycemic insulin clamp, but it is a complicated procedure. In this study, oral glucose tolerance test (OGTT) was used and it is highly correlated with the euglycemic clamp. 12 Repeated blood transfusions result in accumulation of iron in the parenchyma of had IGT and 6% had DM). None had insulin resistance, so it was still a question how DM developed in thalassemic patients in our study. To answer the question, further study comprising hepatitis B and C virus infection and the compliance of iron chelation therapy in thalassemic patients should be done. Diabetes screening in thalassemic patients should be performed every six months. All patients with abnormal glucose tolerance should receive intensive chelation therapy. All thalassemic patients who are seronegative to hepatitis B virus should receive hepatitis B vaccination. 
